Quick Answer
Sagimet Biosciences Inc. reported Stockholders Equity of $111.38 million for fiscal year 2025.
Sagimet Biosciences Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $111.38M | -28.5% |
| 2024 | $155.81M | +71.1% |
| 2023 | $91.06M | +148.7% |
| 2022 | -$186.95M | -18.1% |
| 2021 | -$158.26M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $119.25M | -30.1% | -8.4% |
| June 30, 2025 | $130.16M | -29.0% | -6.4% |
| March 31, 2025 | $138.99M | -26.9% | -10.8% |
| December 31, 2024 | $155.81M | +71.1% | -8.7% |
| September 30, 2024 | $170.68M | +74.4% | -6.9% |
| June 30, 2024 | $183.29M | +192.4% | -3.5% |
| March 31, 2024 | $190.02M | +198.6% | +108.7% |
| December 31, 2023 | $91.06M | +148.7% | -7.0% |
- Sagimet Biosciences Inc. showed a decrease of -28.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2021–2025 period, Sagimet Biosciences Inc.’s stockholders equity has grown by 170.4% (from -$158.26 million to $111.38 million).
- The most recent figure is from Sagimet Biosciences Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: